Healthy Returns: Why people quit weight loss, diabetes drugs within one year
A new study examines how cost, side effects, and other factors influence whether people stop GLP-1s, while Noom cuts staff to focus on GLP-1 products.
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?
Medications known as glucagon-like peptide 1 (GLP-1) receptor agonists are taking over the healthcare industry. While you may not be familiar with the term "GLP-1," I'd wager you'll recognize some of the most popular ones on the market today, including Ozempic, Wegovy, Mounjaro, and Zepbound.
New study reveals why patients stop taking GLP-1 obesity drugs
Tricia Rodriguez, Truveta senior applied research scientist & lead study author, explains the study findings concerning why GLP-1 users stop taking the drug.
Global Partners (GLP) Soars 6.8%: Is Further Upside Left in the Stock?
Global Partners (GLP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns
Dr. Reddy's Lab is undervalued due to exaggerated concerns about Revlimid revenue decline and the underappreciated potential of new high-growth products like biosimilars and GLP-1 drugs. Despite the anticipated Revlimid revenue drop, RDY's new product launches in biosimilars and GLP-1 segments are expected to offset losses, driving future growth. RDY's current P/E ratio of 17.7x is near historical lows; a conservative 23x PE, which is equal to the peer median and slightly lower than the median of the historical range.
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
For the last couple of years, the pharmaceutical sector has become infatuated with glucagon-like peptide 1 (GLP-1) agonists used to treat diabetes and help with chronic weight management. While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (LLY 2.45%) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound.
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
Eli Lilly (LLY 1.57%) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
Hims & Hers Health: The Market Is Likely Wrong
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims' innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.
GLP-1s and Brian Thompson's killing loom large at top health-care conference
Thousands of health-care executives descended on JPMorgan's annual health-care conference in San Francisco this week. The conference took place a month after UnitedHealthcare CEO Brian Thompson was fatally shot in New York City.
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recently surprised investors when it cut its full-year revenue guidance ahead of an investor conference after sales of its GLP-1 drugs fell short of expectations.
